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Abstract
Background: Pneumonia is an important cause of illness and death, particularly in elderly adults. This retrospective
study was conducted to estimate the trend of hospitalization for pneumonia in the Veneto from the records of all
hospitals in the region (serving a population of 4.81 million) during the years 2004 through 2012.
Methods: The cases of pneumonia identified in the hospital discharge records were all cases in which the first-listed
diagnosis was pneumonia, or meningitis, septicemia or empyema associated with pneumonia. The annual total and
age-specific hospitalization rates and trends were calculated and correlated with vaccine coverage. Total related costs
were also calculated.
Results: There were 110,927 hospitalizations for pneumonia, meaning an annual rate of 256.3/100,000 population, with
peaks in children and elderly people. The overall pneumonia-related hospitalization rate did not change significantly
during the study period (AAPC: 1.3% [95% CI: −0.5, 3.1]). The rate dropped significantly among the 0- to 4-year-olds,
however, from 617.3/100,000 in 2004 to 451.8/100,000 in 2012 (AAPC: −2.5% [95% CI: −4.5; −0.5]), while it increased
slightly in adults aged 80+ (AAPC: 1.2% [95% CI: −0.9; 3.4]). The overall pneumonia-related mortality rate was 10.7%.
The estimated cost per hospitalized patient was €3,090.
Conclusion: This study shows that hospitalization for pneumonia has a considerable impact on the health services,
especially for children and the elderly. No decline in hospitalization rates was seen for the very elderly after the
introduction of pneumococcal conjugate vaccination for children.
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Background
Pneumonia is an important cause of illness and death,
particularly for the elderly. There have been reports of
rising numbers of hospital admissions for pneumonia in
some industrialized countries [1-4], which may be due
to their aging populations and a higher prevalence of
concomitant clinical conditions (e.g. chronic obstructive
pulmonary disease or diabetes). This trend has recently
been reversed, however, since the introduction of
pneumococcal conjugate vaccine [5].
The World Health Organization estimates that the
most common bacterial cause of pneumonia in adults
living in industrialized countries is Streptococcus pneumo-
niae (SP), and pneumococcal infections are considered a
major public health issue worldwide for all age groups.
The pathogen reportedly identified as being responsible
for pneumonia may vary, however, depending on the
capacity of the in-hospital laboratory involved, the study
design used in reports, the season, and the region where
studies are conducted [6].
Pneumococcal pneumonia coincides with bacteremia
in 10-30% of patients, in which case it is classified as
invasive. It can cause a number of diseases of variable
severity, and when the pathogen invades normally sterile
sites like the bloodstream and meninges, the resulting
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forms of pneumococcal disease are again classified as in-
vasive [7]. The other two forms of invasive disease are
septicemia and meningitis. Septicemia is a severe blood-
stream infection that can rapidly become life-threatening.
Patients are generally treated at a hospital’s intensive care
unit. The condition is often fatal despite treatment, and
survivors are likely to have permanent organ damage, cog-
nitive impairment, and physical disability. As for bacterial
meningitis, the epidemiological features of this condition
have changed dramatically in recent decades, and the
most common cause of bacterial meningitis among youn-
ger and older adults is currently SP [8].
The aim of the present study was to estimate the
burden of pneumonia in the Veneto Region by assessing
the hospital records of pneumonia-related discharges in
relation to changes in pneumonia vaccination strategies
in the last ten years.
Methods
A retrospective study was conducted in the Veneto Region
(North-East Italy) using the National Surveillance System
hospital database. To estimate the annual hospitalization
rates for pneumococcal disease, we analyzed the hospital
records dating from 1 January 2004 to 31 December 2012
concerning all discharges from all public and accredited
private hospitals. In general, the first-listed diagnosis
concerned the main condition identified during the
patient’s hospital stay, while other diagnoses indicated
associated or contributing conditions (comorbidities and/
or complications).
During the 9 years considered, the Veneto had an
average population of 4.81 million year by year, and an
average 0.81 million hospitalizations a year, which de-
creased from 0.88 to 0.71 million from 2004 to 2012.
The mean number of hospital beds was 19,804 with a
continuous downward trend from 20,338 in 2004 to
18,892 in 2012 (3.81 hospital beds per 1,000 population).
In 2012, the overall hospitalization rate was 136.4 per
1,000 population, for a hospital bed occupation rate of
75% and a mean hospital stay of 7.2 days.
All hospital discharge records containing one of the
following codes according to the International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) were selected: pneumonia 480.xx-486.xx,
487.0; meningitis 321.xx, 013.0.x, 003.21, 036.0, 036.1,
047, 047.0, 047.1, 047.8, 047.9, 049.1, 053.0, 054.72,
072.1, 091.81, 094.2, 098.82, 100.81, 112.83, 114.2,
115.01, 115.11, 115.91, 130.0, 320, 320.0, 320.1, 320.2,
320.3, 320.7, 320.81, 320.82, 320.89, 320.8, 320.9, 322,
322.0, 322.9; septicemia 038.1x, 038.4x, 003.1, 020.2,
022.3, 031.2, 036.2, 038, 038.0, 038.2, 038.3, 038.8, 038.9,
054.5, 790.7; empyema 510.xx. All pneumonia-related hos-
pitalizations were identified from the hospital discharge
records with a first-listed diagnosis of pneumonia or a
first-listed diagnosis of meningitis, septicemia or empyema
associated with pneumonia in another diagnostic field.
We also identified the hospital discharge records using the
codes 481.xx, 038.2 and 320.1 in order to further analyze
SP-related hospitalization.
Annual total and age-specific hospitalization rates were
obtained by dividing the annual number of hospitalizations
for pneumonia by the annual population according to the
Veneto Regional Authority’s statistical office, expressing the
rates as hospitalizations per 100,000 population. For
patients readmitted within 30 days only the first hospital
stay was considered when calculating the hospitalization
rates. The mean days of hospital stay and case-mortality
rates (%) were also calculated.
In the Veneto Region, an immunization program with
7-valent pneumococcal conjugate vaccine (PCV7) was
first introduced in 2001 as an optional vaccination only
for newborn at risk (2–3 and 14 months old), then in
2005 the program was extended to offer vaccination to
all children. In 2010, the 13-valent pneumococcal conju-
gate vaccine (PCV13) was adopted instead of the PCV7
vaccine, and a catch-up program was implemented for in-
fants up to 36 months old. The vaccination coverage rate
was <10% from 2004 to 2006 (low PCV7 coverage), <85%
from 2007 to 2008 (moderate PCV7 coverage), and >90%
since 2009 (high PCV7 coverage up until 2010, then high
PCV13 coverage in 2011 and 2012). In the cohort of
65-year-old people, the 23-valent pneumococcal poly-
saccharide vaccine (PPV23) was optionally offered and
reached a low coverage (about 30%) throughout the study
period.
We checked the other diagnostic codes to identify
the following chronic comorbidities: diabetes mellitus
(ICD9-CM code: 250), heart diseases (ICD9-CM codes:
410–414; 402.01, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91,404.93, 452, 428), cerebrovascular diseases (ICD9-
CM codes: 430–434, 436–438), respiratory diseases (ICD-
9-CM codes: 491.1-491.8; 492–496), malignant neoplasms
(ICD-9-CM codes: 140–209), renal diseases (ICD-9-CM
codes: 580–588, 591) and dementia (ICD-9-CM codes:
290, 331).
Significant trends over the period considered were
assessed as average annual percent changes (AAPC), a
summary measure of the trend over a given fixed inter-
val [9]. An AAPC of zero coincides with the hypothesis
of a trend that is neither increasing nor decreasing. The
95% confidence interval (95% CI) was calculated and a p
value <0.05 was considered significant.
The hospitalized patients’ diagnosis-related groups
(DRG), including readmissions within 30 days, were used
to estimate the costs of their hospitalization to the
healthcare system. The DRGs were calculated with the
Core Grouping System Software considering ICD code,
age, sex, and resource consumption [10]. Each group
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has a similar weight in terms of hospital costs and it
can be applied to each patient. The total cost was cal-
culated taking the total number of hospital discharges
into account. These data may be useful for developing
cost-effectiveness models with a view to establishing
priorities and strategies, and to assessing the impact of
pneumococcal vaccination.
The data obtained from the Regional Statistics Office
were analyzed using EPI-Info 2000 software (Center for
Disease Control and Prevention of Atlanta, GA, USA)
and the Joinpoint Regression Program, rel. 4.0.4. of May
2013 (Statistical Research and Applications Branch, National
Cancer Institute, USA).
The study was conducted on data routinely collected
by the health services and linked to anonymized records
that make it impossible to identify the individuals con-
cerned. Data in the Local Health Authority registries are
recorded with the patient’s consent and can be used as
aggregated data for scientific studies without further
authorization [11]. This study complies with the Helsinki
Declaration and with Italian privacy law n. 196/2003 on
the protection of personal data and it was approved by
the Ethical Committee of Padua Hospital.
Results
Overall, we identified 116,198 hospitalizations associated
with pneumonia. After omitting the 5,271 (4.5%) readmis-
sions within 30 days, the remaining 110,927 included
108,278 (97.6%) for which the first diagnosis was pneumo-
nia. In the other cases associated with pneumonia, the first
diagnosis was septicemia in 2,014 (1.8%), meningitis in
388 (0.3%) and empyema in 247 (0.2%).
The characteristics of the sample are shown in Table 1.
Overall, 53.6% of the patients were male (59,442 cases)
and the highest proportion of hospitalizations was recorded
among ≥65-year-olds (68.9%). Patients were Italian in
95.6% of cases. In the sample as a whole, 46.4% of patients
had at least one chronic comorbidity, and comorbidities
tended to increase with age. The overall average hospital
stay was 11.6 ± 10.1 days, and did not vary between gen-
ders. The average hospital stay increased with age, reach-
ing 13.2 days for patients aged 65 or more. The estimated
overall annual cost of these pneumonia-related hospitali-
zations was approximately €40 million, with an estimated
cost per patient of €3,090. People over 65 accounted for
67.6% of the estimated overall pneumonia-related cost
(€27 million in all, corresponding to €28.7 per person over
65 in the general population). As for outcome, the overall
pneumonia-related mortality rate was 10.7% and remained
stable during the study period. This rate increased with
age, peaking in people over 80 (18.6%) (Figure 1). The
annual pneumonia-related hospitalization rate during
the study period was 256.3 per 100,000 population
(280.8/100,000 males and 232.9/100,000 females). Both
genders showed two age-related peaks, one in children
aged 0–4 years, the other in the elderly, with four-fold
higher rates among people aged 80 or more (Figure 2).
The overall pneumonia-related hospitalization rate
increased slightly, but not significantly between 2004 and
2012, from 232.0/100,000 in 2004 to 262.2/100,000 in
2012 (AAPC 1.3% [95% CI: −0.5, 3.1]). The rate remained
fairly constant in the age groups from 5 to 79 years old
throughout the study period (p = n.s.), but it dropped sig-
nificantly among the 0- to 4-year-olds, from 617.3/100,000
in 2004 to 451.8/100,000 in 2012 (AAPC: −2.5%; [95%
CI: −4.5; −0.5]), while it rose though not significantly,
for adults aged 80 or more (AAPC: 1.2%; [95% CI: −0.9;
3.4]) (Figure 3).
The diagnosis in the hospital discharge records referred
specifically to SP in 2.4%, 87.9%, 21.0% and 13.8% of cases
of pneumonia, meningitis, septicemia and empyema, re-
spectively. Patients were male in 54.9% of cases; the mean
age was 51.2 ± 31.7, and the in-hospital mortality rate was
8.3%.
The age-specific pneumonia-related hospitalization trend
was much the same as the overall pneumonia-related
hospitalization trend: for infants aged 0–4 years, it was
stable from 2004 to 2008, then dropped from 49.9/100,000
in 2009 to 23.3/100,000 in 2012 (p = n.s.); the trend
remained stable in the age groups from 5 to 79 years
(hospitalization rate 5.5/100,000); and it rose for adults
aged 80 or more, from 18.6/100,000 in 2004 to 40.1/
100,000 in 2012 (p = ns).
As concerns PCV coverage and the type of vaccine used,
the pneumonia-related hospitalization rates were highest
for the youngest and oldest age group throughout the
study period, the rates for 0- to 4-year-olds being similar
to those among 65- to 79-year-olds (around 500/100,000).
In 2011–2012, the hospitalization rates dropped for infants
aged 0–4 and children aged 5–14, while they remained
stable for adults aged 65 or more (Figure 3).
Discussion
It is not easy to estimate the morbidity of pneumonia
in the general population. This is partly because the
currently-available epidemiological picture is hazy due
to differences in study designs, population profiles,
access to healthcare, and registration methods. There
is also the fact that most patients developing pneumo-
nia in our Region are not admitted to hospital, so the
pneumonia-related hospitalization rates are bound to
underestimate the burden of the disease. The hospital
records can nonetheless provide a picture of the more
severe cases [12].
The present study examined pneumonia-related hospital
admissions in a large cohort and the results show that
this disease places a heavy burden on hospital resources
and is an important public health issue. The overall
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Figure 1 Number of hospitalizations and mortality rate by age group.
Table 1 Hospital admissions for pneumonia in the Veneto Region by patients’ characteristics and age group
(2004–2012)
Total Age groups
Characteristics 0-4 5-14 15-64 65-79 80+
(n. 110,927) (n. 11,430) (n. 4,765) (n. 18,299) (n. 28,886) (n. 47,547)
Gender [n (%])
Males 59,442 (53.6) 6,151 (53.8) 2,575 (54.0) 11,266 (61.6) 18,181 (62.9) 21,269 (44.7)
Females 51,485 (46.4) 5,279 (46.2) 2,190 (46.0) 7,033 (38.4) 10,705 (37.1) 26,278 (55.3)
Nationality [n (%])
Italian 106,031 (95.6) 9,382 (82.1) 4,147 (87.0) 16,546 (90.4) 28,583 (99.0) 47,373 (99.6)
Foreign 4,896 (4.4) 2,048 (17.9) 618 (13.0) 1,753 (9.6) 303 (1.0) 174 (0.4)
First listed diagnosis [n (%])
Pneumonia 108,278 (97.6) 11,270 (98.6) 4,704 (98.7) 17,587 (96.1) 28,003 (96.9) 46,714 (98.2)
Septicemia 2,014 (1.8) 79 (0.7) 20 (0.4) 424 (2.3) 714 (2.5) 777 (1.6)
Meningitis 388 (0.3) 36 (0.3) 11 (0.2) 183 (1.0) 130 (0.5) 28 (0.1)
Empyema 247 (0.2) 45 (0.4) 30 (0.6) 105 (0.6) 39 (0.1) 28 (0.1)
Comorbidity [n (%])
Heart diseases 19,163 (17.3) 3 (0.0) 3 (0.1) 695 (3.8) 5,229 (18.1) 13,233 (27.8)
COPD and asthma 11,466 (10.3) 366 (3.2) 141 (3.0) 1,232 (6.7) 4,321 (15.0) 5,406 (11.4)
Diabetes mellitus 11,302 (10.2) 3 (0.0) 10 (0.2) 1,478 (8.1) 4,443 (15.4) 5,368 (11.3)
Dementia 9,393 (8.5) 0 (0.0) 0 (0.0) 119 (0.7) 1,933 (6.7) 7,341 (15.4)
Stroke 7,511 (6.8) 2 (0.0) 2 (0.0) 257 (1.4) 2,023 (7.0) 5,227 (11.0)
Renal disease 6,892 (6.2) 19 (0.2) 28 (0.6) 622 (3.4) 2,030 (7.0) 4,193 (8.8)
Cancer 5,951 (5.4) 27 (0.2) 30 (0.6) 975 (5.3) 2,625 (9.1) 2,294 (4.8)
Hospital stay (days [SD]) 11.6 (10.1) 4.7 (3.6) 5.1 (3.7) 10.9 (10.0) 13.2 (10.1) 13.2 (10.6)
Hospitalization cost/year [million €] 40.0 4.5 1.9 6.6 10.5 16.5
COPD: chronic obstructive pulmonary disease.
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pneumonia-related hospitalization rate of 256.3/100,000
identified during the study period showed a slight predi-
lection for male gender (with 1.2 times as many cases as
among females), and confirmed that children and the
elderly are at higher risk of hospitalization for pneumonia
than younger adults. Among patients over 85, pneumonia
is also associated with co-morbidities and a mortality rate
that make it difficult to manage outside the hospital.
The Veneto Region has achieved a greater accuracy in
diagnosing pneumonia by revising its guidelines on the
Figure 2 Pneumonia-related hospitalization rate in the Veneto Region by age group and gender (2004–2012).
Figure 3 Pneumonia-related hospitalization rate (per 100,000 population) in the Veneto Region by age group (2004–2012).
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ICD-9-CM codes used in hospital discharge records in
2010: this may have led to an underestimation of the
drop in the number of cases among children and an
overestimation of the rising figures for the elderly over
the last two years of our study period [10]. Nonetheless,
our data revealed a significant decline in the hospitalization
rate for pneumonia among children in recent years, coin-
ciding with the introduction of PCV13 in lieu of PCV7,
which provides coverage for six more serotypes, including
3, 1, 19A and 7 F, and its adoption was also associated
with a catch-up strategy [13]. A significant reduction in
hospitalization rates for pneumonia generally, and for
pneumococcal pneumonia was reported for the first time
in Italy among children aged 0–24 months in Liguria [14],
and also more recently in the Apulia Region [15].
In 20-60% of cases, community-acquired pneumonia is
attributable to SP, although only a small percentage of
these cases are identified as such [16] (it is estimated
that, when the microorganism is not specified, about
36% of cases are attributable to SP infection [6]). In our
sample, SP was specifically diagnosed in 2.4% of cases; this
proportion varied depending on the first-listed diagnosis,
being lower for pneumonia and higher for meningitis. A
recent review on the burden of community-acquired
pneumonia in Europe found that Italy had the lowest
pneumococcus identification rate. This points to the need
to improve the tests used to diagnose pneumonia because
a more accurate pneumococcus detection would provide a
clearer picture of the true burden of community-acquired
pneumonia [6].
As reported by other Authors [5], we found no declining
hospitalization rate for the most elderly (80+), and this
epidemiological picture could be due to various factors.
The magnitude of the indirect effects of vaccine-derived
immunity depends on multiple influences relating to
the transmissibility of the infection, the nature of the
vaccine-induced immunity, the patterns of mixing and
transmitting infections in a given population, the dis-
tribution of the vaccine and, more importantly, the
population’s immunity. The nuances of immunity and
the complexity of population heterogeneity make pre-
dictions difficult [17,18]. The Veneto Region’s active
surveillance system for monitoring invasive bacterial
diseases shows that serotypes not covered by the 7-valent
pneumococcal conjugate vaccine, such as 19A, play a sig-
nificant part [19], suggesting the likelihood of a reversal of
the herd effect [20].
The risk of pneumonia increases considerably with age
and it is important to ensure a good vaccination coverage
for both influenza and pneumococcus among older people.
In the latter period of our study, the annual influenza
vaccination coverage of the elderly population dropped
from about 75% in 2004 to about 60% in 2012, meaning
that other measures are needed to prevent pneumonia
in seniors [21]. Immunization with PPV23 has been
implemented differently in our area in recent years,
generally reaching very low overall coverage rates even
among people with medical indications. In addition, tri-
als conducted on PPVs have failed to provide evidence
to support the routine use of PPV to prevent all-cause
pneumonia or mortality, and some studies indicate that
PPVs confer little protection against invasive pneumo-
coccal diseases [22-24]. Prevention remains the most
valuable tool to help reduce the burden of pneumonia,
and vaccination strategies can be used for the primary
prevention of infection and possibly to reduce this bur-
den in all age groups. The availability of new-generation
pneumococcal conjugate vaccines with a broader anti-
genic spectrum and suitable for people of all ages suggests
interesting new opportunities for improving the control of
pneumococcal disease in the population as a whole. This
strategy has had a significant impact on the burden of
pneumonia in areas where the vaccines have been intro-
duced and a good coverage has been achieved (5, 14–15).
The introduction of PCV13 for our Region’s newborn in
2010, and its subsequent use in people over 65 years old
[13,25] can be expected to produce some benefits in
years to come. A better understanding of the effects of
higher-valence vaccines can improve the sensitivity of
surveillance systems and add to our knowledge of the
potential invasiveness of non-PCV serotypes, as mea-
sured by comparing the prevalence of their carriage with
their prevalence in invasive pneumococcal disease. This
is an aspect of surveillance that has hitherto been largely
overlooked.
A drawback of using hospital discharge records lies in the
difficulty of distinguishing between community-acquired
pneumonia and hospital-acquired pneumonia. Our data
(for more than 97% of our sample) are based on first ad-
missions for pneumonia, and most cases were probably
community-acquired because hospital-acquired infections
are not normally recorded as a first diagnosis. We only
considered admissions for which pneumonia was a sec-
ondary diagnosis (2.4% of the sample) if the first diagnosis
was septicemia, meningitis, or empyema. This was done
to assess the potential impact of vaccination, which might
be more effective on community-acquired pneumonia and
less so on hospital-acquired pneumonia, because of the
different types of agent pathogen involved [26,27].
Conclusions
In conclusion, this study shows that hospitalization for
pneumonia has a considerable impact on the health ser-
vices, especially for children and the elderly. We identified
a reduction in the pneumonia-related hospitalization rate
in children, especially in the latter part of the period con-
sidered, while it increased slightly in the elderly. The most
appropriate prevention measures need to be defined to
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deal with these epidemiological patterns of hospital ad-
missions for pneumonia to prevent worsening outcomes
and higher costs in future.
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